Thursday, June 11, 2026
🇺🇸 FDA

Intelligence · INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Recently updated

FDA-approved

Showing page 128 of 200 · By data quality, then INN

  1. interferon alfa-2b

    INTRONA

    FDA: approved · EMA: withdrawn

    L03AB05

  2. interferon alfacon-1

    INFERGEN

    EMA: withdrawn

    L03AB09

  3. interferon beta-1a

    BIFERONEX

    FDA: approved · EMA: approved

    L03AB07

  4. iodine (131i) omburtamab

    OMBLASTYS

    EMA: refused

    V10XA

  5. ioflupane (123i)

    CELSUNAX

    EMA: approved

    V09AB03

  6. ioflupane (123l)

    STRIASCAN

    EMA: approved

    V09AB03

  7. iptacopan

    FABHALTA Novartis Pharmaceuticals

    EMA: approved · TGA: approved

    L04A

  8. irinotecan hydrochloride trihydrate

    ONIVYDE PEGYLATED LIPOSOMAL (PREVIOUSLY ONIVYDE)

    EMA: approved

    L01CE02

  9. iron oxide

    SINEREM

    EMA: application withdrawn

  10. isatuximab

    SARCLISA

    EMA: approved · PMDA: approved · NMPA: clinical trials

    L01XC38

  11. isavuconazole

    CRESEMBA

    EMA: approved

    J02AC05

  12. japanese encephalitis vaccine (inactivated, adsorbed)

    IXIARO

    EMA: approved

    J07BA02

  13. l-acetylleucine

    AQNEURSA

    EMA: approved

    N07XX27

  14. lapatinib

    TYKERB Novartis Pharmaceuticals

    EMA: approved · TGA: approved

    L01EH01

  15. laropiprant

    TREVACLYN

    EMA: withdrawn

    C10AD52

  16. larotrectinib

    VITRAKVI Bayer Australia Ltd

    EMA: approved · TGA: approved

    L01XE53

  17. lasmiditan

    RAYVOW

    FDA: approved · EMA: approved

    N02CC08

  18. lasofoxifene

    FABLYN

    EMA: unknown

    G03

  19. latanoprost / netarsudil

    ROCLANDA

    EMA: approved

    S01EE

  20. lazertinib

    LAZCLUZE

    EMA: approved

    L01EB09

  21. lecanemab

    LEQEMBI

    EMA: approved · PMDA: approved

    N06DX04

  22. ledispavir

    HARVONI

    EMA: approved

    J05AX65

  23. lefamulin

    XENLETA

    EMA: approved

    J01XX

  24. lenadogene nolparvovec

    LUMEVOQ

    EMA: application withdrawn

    S01

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles — INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page — it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.